EC approves UCB's Briviact

UCB Group (Euronext:UCB) said the European Commission approved Briviact brivaracetam as an adjunct therapy to treat partial-onset seizures in epileptic patients aged 16 and older. The approval is the first worldwide for the high affinity synaptic vesicle protein ( SV2A) ligand.

UCB spokesperson France Nivelle told BioCentury the company would launch Briviact this quarter in select territories, with more to follow over several months. Nivelle declined to comment on the therapy's price. ...